Bemarituzumab is under investigation in clinical trial NCT03694522 (A study of Bemarituzumab (FPA144) combined with modified FOLFOX6 (Mfolfox6) in gastric/gastroesophageal junction cancer). Bemarituzumab is designed to block fibroblast growth factors from binding to and activating fibroblast growth factor receptor 2 (FGFR2), therefore inhibiting several downstream pro-tumor signaling pathways and potentially slowing tumor growth.
Bemarituzumab Biosimilar Antibody
$205.00 – $2,500.00
Bemarituzumab is a humanized immunoglobulin (Ig) G1-kappa monoclonal antibody against human fibroblast growth factor receptor 2 (FGFR2) protein.
Host/Isotype: Human/IgG1
Class: Monoclonal
Immunogen: Human FGFR2 protein
Production platform: CHO cells
Purification: Affinity chromatography
Storage buffer: PBS, pH 7.2
Storage condition: –20°C
For Research Use Only. Not for use in clinical diagnostics or therapeutics.
Additional information
Antibody Production Scale | 50 ug, 250 ug, 1 mg |
---|---|
Conjugate | None, FITC, HRP, ADC (custom drug) |
You must be logged in to post a review.
Reviews
There are no reviews yet.